LONDON (Reuters) -AstraZeneca raised its annual earnings forecast on Thursday, helped by strong demand for its cancer drugs, and moved to boost its pipeline in the booming anti-obesity market with a deal costing up to $2 billion. The Anglo-Swedish company reported third-quarter profit and revenue just ahead of analyst expectations. For the third consecutive quarter, strong sales of its blockbuster cancer treatments and healthy demand in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy.
Sweden
London
City-of
United-kingdom
Bengaluru
Karnataka
India
Swedish
Britain
Maggie-fick
Mark-potter
Nivedita-bhattacharjee